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INTRODUCTION 
 
 
 Proper dosage of gene and chromosome copy is essential in normal development. Gene 
dosage refers to the amount of gene product. Copy number refers to the number of copies of a gene 
present in a genome. Copy number variations (CNVs) are segments of DNA that are 1 kilobase or 
larger in which insertion or deletion events have occurred1. These DNA segments exist in a 
variable copy number compared to the reference genome. CNVs can influence genes or gene 
regions, such as those in livestock production traits. Dosage compensation is the balancing of 
expression between male and female sex chromosomes and between the sex chromosomes and the 
autosomes2. Dosage compensation mechanisms exist in eutherian mammals3, marsupials4, 
monotreme mammals5, birds6, and the non-mammalian invertebrates C. elegans7 and D. 
melanogaster8. In eutherian mammals, dosage between male and female sex chromosomes and 
between the sex chromosomes and the autosomes must be balanced. The evolution of the sex-
determining chromosomes X and Y led to a single functional X being present in males, while two  
X’s exist in females. Without a mechanism to compensate, X-linked gene expression would be 
unequal between the sexes due to ‘X aneuploidy’ in males9 (Figure 1).  
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Figure 1. Ohno’s hypothesis of dosage compensation in mammals, flies (D. melanogaster), and 
worms (C. elegans). In flies, X chromosome transcription is increased in males (XY) to 
compensate for X monosomy compared to the autosomes and to balance expression of the male X 
chromosome with the female X chromosomes. In worms, the X chromosome is upregulated in 
males (XO) to compensate for X monosomy. Upregulation of the X chromosome in female (XX) 
worms is counteracted by a female-specific dosage compensation mechanism, effectively 
balancing the sex chromosomes in males and females and with respect to the autosomes. Worms 
can be XX hermaphrodites and dosage compensation downregulates both X’s by a factor of two 
to balance with the dosage of XO males. In mammals, the X chromosome is upregulated in both 
males (XY) and females (XX) followed by inactivation of one of the X chromosomes in females 
to balance the dosage of the sex chromosomes in males and females and with respect to the 
autosomes. From Ercan et al., 2015.  
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 Aneuploidies are chromosomal deviations from the normal diploid dosage of an animal 
that reduce fitness and are usually lethal10,11. Human chromosome 21, the smallest chromosome 
containing the fewest genes, deviates from diploid due to non-disjunction in meiosis I where 
homologous chromosomes do not separate resulting in trisomy 2112,13. Trisomy 21 or Down’s 
Syndrome has variable and complex clinical presentation including distinct facial dysmorphology, 
a brain that is smaller and hypocellular, and cognitive impairment12. Conversely, mammalian 
males have monosomy of the X chromosome when compared to mammalian females and are 
phenotypically normal. Aneuploidies of the X chromosome include Turner’s syndrome (XO 
female), and Klinefelter’s syndrome (XXY male). Characteristic features of Turner’s syndrome 
include short stature and gonadal development failure, while Klinefelter males have taller stature, 
lower muscle tone, and decreased gonadal development14. X chromosome dosage compensation 
in mammals explains X chromosome regulation in the sex chromosome disorders Turner’s 
syndrome and Klinefelter’s syndrome and how males survive ‘X aneuploidy’.   
 
 Ohno hypothesized that X-linked gene expression is doubled in both males and females, 
successfully balancing with the autosome expression in males15. Dosage compensation is 
necessary because in mammals, the X chromosome is large and gene rich and the Y chromosome 
is small and gene poor. The sex chromosome system in mammals denotes female mammals as XX 
and males as hemizygous with genotype XY. Due to dosage compensation, X-linked genes in 
males have a twofold upregulation. In females, the upregulation results in an overexpression from 
both X chromosomes and lead to the downregulation of an X chromosome to restore balance16 
(Figure 1). Dosage compensation is well studied in humans and mice, but little research has been 
done in other domestic species.  
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 Another mechanism that helps achieve dosage compensation in mammalian females is X-
chromosome inactivation (XCI) which randomly and globally inactivates one of the X-
chromosomes17. X chromosome inactivation is unique to mammals18, including monotremes19, 
marsupials20, and eutherians21, but this thesis will focus mainly on dosage compensation and X 
chromosome inactivation in eutherian mammals.  
 
 Dosage compensation is species, tissue, and developmental stage specific, these 
differences warrant the need to study each species independently22. There is current debate in the 
scientific community over the confirmation of Ohno’s hypothesis of dosage compensation in 
eutherian mammals. The debate is fueled by the difference in RNA sequencing and microarray 
experiments and differences in data analysis. Studies that reject Ohno’s hypothesis of dosage 
compensation have included actively expressed, weakly expressed, and silent genes in their 
analysis. Xiong et al analyzed publicly available RNA-sequencing datasets and reported an X:AA 
ratio of ~0.5 and rejected Ohno’s hypothesis23. Two additional studies have also rejected Ohno’s 
hypothesis24,25. Later studies that have re-analyzed this dataset and other generated datasets, have 
reported an X:AA ratio around 1.0 and support Ohno’s hypothesis3,9,26,27. These studies have only 
included actively expressed genes in their analysis of dosage compensation.  
 
 Sheep are a valuable model to study dosage compensation because little is known about 
dosage compensation in sheep and many production traits are linked to X-linked genes in sheep28. 
These X-linked genes are important in reproduction, linked to the immune system and disease, 
involved in biosynthetic pathways, and have human orthologs28. Genes on the X chromosome are 
evolutionarily conserved across mammalian species. X-linked genes that are X-specific have 
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single expression due to X chromosome inactivation in females and XY males. Recombination 
between the X chromosome and autosome has been selected against because it would disrupt 
dosage compensation29,30.  
 
Maternal nutrition studies are valuable to sheep producers and sheep have been historically 
used as a model for human pregnancy31,32. Previous studies in Ovis aries have shown that maternal 
nutrition can produce gene expression changes in fetal tissues33. During the change in seasons, 
forage quality and quantity also changes and results in over and undernutrition of pregnant ewes. 
When forage quality and quantity are low in the fall and winter, intrauterine growth restriction 
(IUGR) occurs and poor growth of the developing fetus is a consequence. When ewes are fed ad-
libitum feed or graze in high quality pasture, maternal overnutrition is common and affects the 
developing fetus34. Maternal nutrition can induce permanent changes in structure, physiology, and 
metabolism of offspring35.  
 
 Through a collaboration with the labs of Dr. Govoni, Dr. Reed, and Dr. Zinn, we obtained 
ovine fetal day 135 tissues of brain, kidney, and lung and characterized dosage compensation in 
the sheep transcriptome by RNA-sequencing. Day 135 of gestation in sheep corresponds to late 
gestation, the maximal fetal growth period33. The effect of maternal overnutrition and 
undernutrition on dosage compensation was also investigated. Investigating the normal pattern of 
dosage compensation is important in understanding abnormalities that occur naturally and through 
biotechnology.  
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CHAPTER 1 
LITERATURE REVIEW 
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1.1 DOSAGE COMPENSATION 
 
Dosage compensation is present in non-mammalian and mammalian species and is 
achieved through different mechanisms such as increased X transcription in only the male or 
increased X transcription in males and females followed by a female-specific dosage compensation 
mechanism (Figure 1)9. In addition to species differences, dosage compensation is known to be 
both developmental stage specific and tissue specific26,36.  Different sex chromosome systems exist 
in different mammalian and non-mammalian species. During the evolution of sex chromosomes 
X and Y in eutherian mammals and marsupials, divergence led to monosomy of the X chromosome 
in males (XY). During the evolution of sex chromosomes Z and W in birds and reptiles, divergence 
led to monosomy of the Z chromosome in females (ZW)16. The Y and W chromosomes became 
sex-limited through loss of gene activity through evolution. Both systems of sex determination 
resulted in an imbalance in gene dosage of X-linked or Z-linked genes in females and males 
respectively37. Susumu Ohno hypothesized that to compensate for monosomy of the sex 
chromosomes X or Z, upregulation of X or Z in the heterogametic sex would be necessary to return 
gene expression of the sex chromosomes to normal diploid level15. It was thought that sex 
chromosome evolution led to complete dosage compensation, as previously observed in C. 
elegans, D. melanogaster, and M. musculus until two independent studies in birds revealed 
incomplete dosage compensation of the Z chromosome38,39. Further investigation of Ohno’s 
hypothesis has revealed incomplete dosage compensation in other species suggesting that a whole-
chromosome regulation method is not employed in in all species16. In species with incomplete 
dosage compensation, there is direct compensation of a subset of genes known as dosage-sensitive 
genes, while loci that do not experience a dose effect are indirectly compensated16. 
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1.1.2 Gene dosage 
 
In diploid organisms, chromosome and gene dosage are closely regulated. Deviation from 
diploid on the gene level can have detrimental consequences and on the chromosome level is 
typically lethal. Aneuploidy is described as a deviation from the normal copy number of an 
individual chromosome40. There are two types of aneuploidy in multicellular organisms, 
conditional aneuploidy and somatic aneuploidy. Conditional aneuploidy has a presence in all cells 
and is marked by adverse effects, while somatic aneuploidy is more selective40. Turner’s syndrome 
and Klinefelter’s syndrome are sex chromosome disorders with aneuploidy of the X 
chromosome41. Mammalian XY males are monoallelic for most X-linked genes, making them a 
functional ‘X aneuploidy’. Autosomal monosomies of chromosomes equal in size to X have lethal 
consequences42. XY males are able to avoid the deleterious effects of X monosomy through dosage 
compensation.  
 
The delicate balance of gene dosage is explained by the evolution of the mammalian sex 
chromosomes. The mammalian XY pair evolved from a pair of autosomes as explained by H.J. 
Muller’s proposed model (1914). Proto-X and proto-Y arose when one of the autosomes gained a 
sex determining locus. Proto-Y then continued to accumulate alleles that were advantageous to 
males, and X and Y recombination was lost43 (Figure 2). The nonrecombining region gained 
mutations, deletions, and insertions of repetitive elements. Genes that did not have a sex-specific 
advantage became inactive and were lost from the Y chromosome43. As genes were gradually lost 
from the Y chromosome, making it haploinsufficient, the genes on the X chromosome had an 
increase in transcription2.While present day X and Y differ in gene content, they share a region of 
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sequence homology called the pseudoautosomal region (Figure 3). The pseudoautosomal region 
of the X and Y chromosome maintains 98-99% similarity in sequence and gene content, 
recombines frequently, has high GC content and high rate of mutation44,45. This region is conserved 
among mammalian species, but displays variation in gene content and size based on the species46. 
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Figure 2. Sex chromosomes in mammals began as a pair of autosomes, proto-X and proto-Y, shown in gray with recombination shown 
with x’s. An autosome pair is shown in green. The male-determining gene Sry initiated sex chromosome evolution in mammals. This 
blocked recombination between proto-X and proto-Y at the region of Sry and nearby genes, leading to the creation of X-specific (pink) 
and Y-specific (blue) regions. During evolution, recombination was further suppressed, the X-specific and Y-specific regions grew 
larger, and X and Y diverged. Pseudoautosomal regions (PARS) are the sections of the X and Y chromosome shown in gray that are 
still able to recombine. The Y chromosome is unable to recombine with the X chromosome in the male-specific region and has lost 
genes, becoming progressively smaller.  From Pessia et al., 2014. 
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Figure 3. The human X and Y chromosomes have pseudoautosomal regions (PARs) which contain 
the same genes and undergo recombination. The X chromosome has an X-specific region and the 
Y chromosome has a Y-specific region which cannot recombine. X and Y chromosome evolution 
occurred in the same manner for mammalian species, but the size of the pseudoautosomal region(s) 
is species dependent.  Adapted from Arnold et al., 2004. 
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1.1.3 Non-mammalian dosage compensation 
 
The molecular mechanisms used to accomplish dosage compensation, although unique for 
the non-mammalian invertebrate species D. melanogaster (fly), C. elegans (worm), and 
mammalian M. musculus (mouse) have many similar elements including dosage compensation 
complex recruitment, a cis-spreading pattern, and transcription and chromatin structure 
regulation47.D. melanogaster are diploid with one X chromosome per set of autosomes in males 
(X:AA) and two X chromosomes per autosome set in females (XX:AA)36. In fly somatic cells, 
male specific lethal complexes are deployed that double the transcription from the male X 
chromosome7 (Figure 1).  
 
In C. elegans, embryos that are XX are female and develop into hermaphrodites that are 
able to self-fertilize internally, but preferentially use XO male sperm when available for 
fertilization7. The X to Autosome (X:A) ratio determines sex and X-linked gene expression level. 
Males are XO with an X:A ratio of 0.5 while hermaphrodites are XX with an X:A ratio of 1.07. 
Dosage compensation in C. elegans involves the decrease to one half the gene expression from 
both X chromosomes in hermaphrodites48. While Drosophila dosage compensation has been well 
studied, evidence for X repression in C. elegans is more recent. Dosage compensation is complete 
in the fly and the worm49,8 . Lastly, in vertebrate birds, fish, and reptiles, dosage compensation 
appears to be partial and gene-specific50.  
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1.1.4 Mammalian dosage compensation 
 
The mechanism of dosage compensation equalizes the X chromosome dose in males and 
females and also minimizes the damaging effects of X-polysomy15. Ohno hypothesized that the 
mechanism of dosage compensation in mammals evolved by first doubling the expression of the 
X chromosome in both males and females. This solved the dosage imbalance problem of X-linked 
genes in males, and then inactivation of a single X chromosome in every cell of females by X 
chromosome inactivation (XCI) balanced gene dosage in both of the sexes15. Both X chromosome 
upregulation and X chromosome inactivation are necessary parts of the dosage compensation 
mechanism in mammals3.  
 
 The status of dosage compensation in mammals has been analyzed with microarray and 
RNA-seq data by computing the mean expression of all X-linked genes to the mean expression of 
all autosomal genes. An X:A ratio of 1.0 indicates doubling of transcription of genes on the X 
chromosome, while an X:A ratio of 0.5 indicates that transcription is not doubled26. While global 
X upregulation has been seen in marsupials, global X upregulation is absent in placental 
mammals4. Partial to full upregulation of dosage sensitive X-linked genes is currently observed in 
eutherian mammals4,3,51.  
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1.1.5 Developmental stage specificity 
 
Dosage compensation in mammalian and non-mammalian species is essential to proper 
development and variation in the degree of dosage compensation can be studied throughout 
different developmental stages. Studies in D. melanogaster and C. elegans have discovered that 
improper dosage compensation is lethal, resulting in the death of C. elegans in embryogenesis or 
early larval stage52,53,54 and male specific lethal mutations in Drosophila55. Also, mouse embryos 
die around day 10 with a lack of XCI56.  
 
In eutherian mammals, the developmental stage when XCI is achieved is unclear and may 
be largely varied among different species57. Okamoto et al. showed that mammalian species have 
diversity in the time that XCI is activated in early embryogenesis and in its regulation21. Random 
X chromosome inactivation transcriptionally inactivates one of the two X chromosomes in each 
cell at random17. In imprinted XCI, the paternally inherited X chromosome is preferentially 
silenced and the maternally inherited X remains active58 (Figure 4).  
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Figure 4. The de novo inactivation model of X chromosome inactivation in mammals is displayed. 
The egg has an active X chromosome and the sperm has an inactive X chromosome that is 
reactivated after meiosis. In the zygote, there are two active X chromosomes, and the paternal X 
(XP) chromosome is re-inactivated beginning at the 4-8 cell stage in mice. In the blastocyst, the 
trophectoderm (extra-embryonic cells in blue) maintains inactivation of XP and causes imprinted 
X-chromosome inactivation in the placenta. In the blastocyst, the inner cell mass (green cells) 
undergo reactivation of XP and then random X-chromosome inactivation. The fetus has random 
X-chromosome inactivation.  From Huynh et al., 2005. 
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Random XCI initiation occurs at or after the blastocyst stage in humans, in cells of the 
morula and early blastocyst stage in rabbits, and in the late blastocyst stage in mice59. In mice, 
imprinted XCI initiation occurs first at the 2-4 cell stage. Another developmental stage specific 
event involves genes termed XCI escaping genes which are located outside the pseudoautosomal 
regions of the X chromosome and have bialellic expression58. In adult mouse tissues, genes 
escaping XCI are first inactivated in the mouse embryo and become reactivated during 
development60. The particular developmental stage in which genes escape X chromosome 
inactivation in humans is unknown61. The differences based on developmental stage highlight the 
advantage to studying early stages in embryonic development in various species to uncover species 
specific time points.  
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1.1.6 Tissue-specificity 
 
Despite the difference in the mechanisms of dosage compensation in Drosophila and 
mammals, tissue-specific variation in dosage compensation has been observed in both species and 
may contribute to sex-biased gene expression62. In mammals, the expression of X-linked genes 
differs by tissue type. There is a high expression of X-linked genes in the brain, significantly higher 
compared to other somatic tissues9. The X chromosomes of mice and humans are enriched for 
genes related to brain function26,63. In addition, in the mouse brain, there is preferential expression 
of genes from the maternal X chromosome, indicating a bias in XCI64. Genes with tissue-restricted 
expression, such as those in the testis, ovary, and brain, accumulate on the sex chromosomes9. In 
pre-meiotic and post-meiotic stages, male specific X-linked genes are largely expressed in the 
testes65,66. X-linked genes that are conserved on chicken orthologs are characterized as the oldest 
X-linked genes and show high expression in mouse and human ovaries67,68  Variation exists in the 
level of completion of XCI in different adult tissues69. X chromosome inactivation in eutherian 
mammals is random in somatic cells and the extra-embryonic structures can either follow random 
or imprinted inactivation.   
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1.1.7 Ovine dosage compensation 
 
As there is no direct research on dosage compensation in the sheep, current research is 
aimed at the comparison of sheep X chromosome to that of the cow and human, pseudoautosomal 
regions, and X-linked genes in sheep with implications in artificial selection. In comparing the 
present day bovine X chromosome, ovine X chromosome, and human X chromosome, increased 
locus order differences were found between the ovine and bovine X chromosome than between 
the ovine and human X chromosome70.  
Studying pseudoautosomal regions can provide insight into sex chromosome evolution. 
Mammalian X and Y chromosomes share a region of sequence homology called the 
pseudoautosomal region (PAR) where recombination occurs during prophase of male meiosis71. 
This region contains 98-99% sequence similarity between the sex chromosomes, the same gene 
content, high GC content, and high recombination frequency71. The ruminant pseudoautosomal 
region is 5-9 Mb in size and shares the same genes as human pseudoautosomal region 1 (PAR1), 
with the exception of the gene PLCXD which is X-specific in ruminants72. The ruminant PAR 
begins with the gene GTPB6P and ends at the gene GPR143, marking the pseudoautosomal 
boundary (PAB)72,73(Figure 5). This indicates that the boundary was established before Bovinae 
and Caprinae diverged ~18 million years ago74. Studying dosage compensation in the sheep can 
bridge the knowledge gap and uncover the mechanism of dosage compensation. The ovine X 
chromosome has been evaluated for artificial selection signatures that are useful in improving the 
desired phenotypic traits and guiding animal breeding28. X-linked genes in sheep are linked to 
reproductive function such as ovulation rate 75,76. Because of sex-specific dosage compensation in 
mammals, X chromosome selection pressure is increased compared to the autosomes, highlighting 
more direct selection on the X chromosome26,43.  
19 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. The Human X chromosome (HSAX) shows the organization of the human 
pseudoautosomal regions (PAR1 and PAR2) and X-specific regions evolutionary strata (S1-S5). 
Pseudoautosomal boundaries are shown in pink text. Human PAR1 is 2.7 Mb starting at the gene 
PLCXD1 and ending at the gene XG and human PAR2 is 0.32 Mb. The ruminant PAR starts at 
the gene GTPB6P and ends at the gene GPR143. The ruminant PAR is 5-9 Mb. The gene PLCXD1 
is X-specific in ruminants and is not located in the pseudoautosomal region. Its location is marked 
by the red line. Adapted from Raudsepp et al 2015. 
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1.2 USING RNA SEQ TO CONFIRM MAMMALIAN DOSAGE 
COMPENSATION 
 
A throughput method that assays the expression of a large number of X-linked and 
autosomal genes is required to study dosage compensation because expressed genes from the entire 
X chromosome and all autosomes are compared 77. Throughput methods include microarray and 
RNA sequencing. Microarray assays a large number of genes with representative probes, but 
limitations exist in cataloguing and quantifying the differences in expression level and diversity of 
RNA molecules78. RNA sequencing is now the predominant method for studying transcriptomics 
and dosage compensation. The advancement of RNA sequencing (RNA-seq) technology 
introduced a high-throughput method where all gene transcripts in the transcriptome can be 
analyzed. RNA sequencing advantages include the ability to validate microarray results, study 
diverse species outside of the standard model organisms, and perform strand specific cDNA 
sequencing to study both sense and antisense transcripts79. Next generation sequencing technology 
continues to evolve, becoming specialized for a multitude of applications and more accessible to 
researchers.  
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1.2.1 Microarray and RNA-seq studies 
 
Since the early 2000’s, microarray data has been analyzed to determine the extent of dosage 
compensation in eutherian mammals. Since 2010, RNA sequencing data has been analyzed and 
different conclusions have been reached on the status of dosage compensation in mammalian 
tissues due to the data analysis parameters and software used. Throughput data is needed to study 
dosage compensation because the mean expression of all the X-linked genes is compared with the 
mean expression of all the autosomal genes. There is current debate on the status of dosage 
compensation in mammalian tissues, with studies supporting Ohno’s hypothesis of dosage 
compensation and studies rejecting Ohno’s hypothesis of dosage compensation.  
 
If X upregulation in males and females plus X inactivation in females are unsuccessful in 
dosage compensation, the X:AA mean expression ratio should be 0.5 in both sexes3. All the 
following studies reject Ohno’s hypothesis of dosage compensation upon RNA-seq data analysis. 
Xiong et al re-analyzed RNA-seq datasets for human tissues80-82, mouse tissues83, and C. elegans 
developmental stages84 and rejected Ohno’s hypothesis due to calculated X:AA median expression 
ratios of 0.3 in mice, 0.5 in humans, and 1.0 in C. elegans embryos declining to 0.4 in C. elegans 
adults23. This group supports their conclusion that the X:AA ratio is ~ 0.5 with the importance of 
comparing actively expressed , weakly expressed, and silenced genes between X and autosomes24.  
Lin et al re-analyzed RNA-seq datasets of chicken, mouse, and human organs85 by comparing 1:1 
orthologs in human to chicken and mouse to chicken and concluded that after normalizing the 
AA:AA ratio to 1.0, the X:XX ratio is ~0.551. These analyses found that comparing all the genes 
on the X chromosome and autosomes reveals a lack of dosage compensation.  
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Microarray data analysis has supported dosage compensation in mammals. If dosage is 
effectively compensated, the X:AA mean expression ratio should be 1.0 in both females and 
males3. All of the following studies support Ohno’s hypothesis of dosage compensation upon 
RNA-seq data analysis. Ngyuen et al analyzed human and mouse microarray datasets and their 
own human tissue generated microarray data and concluded that dosage compensation is achieved 
in humans with an X:AA ratio of 0.94 and in mice with an X:AA ratio of 1.01 and these ratios did 
not show significant difference based on the tissue type26.   
 
The following studies re-analyzed the data in the publication by Xiong et al and declared 
that dosage is compensated in humans, mice, and C. elegans. Pessia et al re-analyzed the human 
tissues RNA-seq dataset and concluded that for dosage sensitive genes that code large protein 
complexes, the X:AA ratio is equal to 0.93.  Kharchenko et al re-analyzed the human and mouse 
RNA seq datasets and an additional mouse RNA-seq dataset by Gregg et al and found that the 
average X:AA ratio using reads per kilobase per million (RPKM ≥ 1)  is close to 1.0 in mouse and 
human tissues, specifically 0.93 ± 0.17 in all human tissues86. Deng et al analyzed Xiong et al’s 
data and newly released RNA-seq datasets, removing skewed X chromosome gene content by 
using fragments per kilobase of exon per million greater than zero (FPKM>0) and found that C. 
elegans achieve dosage compensation with an X:AA ratio of 0.99 in adult animals lacking a 
germline.  
 
In humans and mice, the X:AA ratios with the removal of genes that are weakly expressed 
and silenced reveal that the majority of genes that are expressed from the active X are upregulated 
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and achieve comparable expression with the autosomes9. Lin et al proposed that dosage 
compensation can be effectively studied by measuring only genes that are actively expressed. 
Actively expressed genes in mouse embryonic stem cells, blastocysts and adult lymphocytes, are 
upregulated in both males and females87. Slightly more RNA-seq data analysis studies exist in 
favor of Ohno’s hypothesis, while a final consensus has not been reached, it is clear that 
conclusions are heavily dependent on the analytical approach.  
 
1.2.2 Effect of analytical approach on dosage compensation 
 
RNA-seq data analysis is complex due to the vast number of software options available for 
processing data and the strong effect that the analytical approach can have on the final 
experimental results and conclusions. The scientific debate over the status of dosage compensation 
in mammals has resulted in extensive re-analysis of the same RNA-seq datasets, leading to 
different final conclusions. The factors that affect RNA-seq data analysis include trimming 
parameters, mapping parameters, reference genome annotation, library preparation, and depth of 
sequencing coverage.  
 
Raw RNA-seq reads are trimmed using parameters for quality score and length. Since 
genes expressed at any level can be under selection for dosage compensation, trimming based on 
expression level can skew final X:AA ratio2. Because of the conflicting results of dosage 
compensation studies that calculate the X:AA ratio, RXE and X to proto-X (Z chromosome) 
expression analyses are becoming more popular. The trimming parameters used by Xiong et al 
were too stringent and likely introduced bias into their calculation of the X:AA ratio. Xiong et al 
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utilized unique mapping and discarded reads spanning splice junctions, which results in lower 
Relative X expression (RXE) values. RXE is calculated for all tissues to standardize and compare 
dosage compensation. Relative X expression can be calculated by first doing a log2-transformation 
of FPKM, RPKM, or TPM values, making the data more normally distributed and reducing 
outliers. Next, the mean autosomal expression is subtracted from the mean X chromosome 
expression (i.e. relative X expression (RXE)= log2(X)- log2(A))2.  
 
X to proto-X (Z chromosome) expression analyses compare the expression of X-linked 
genes in one species to their autosomal orthologs in another species4. Genes with 1:1 orthologs in 
chickens and humans have recently been studied by RNA-seq analysis of an amniote-wide 
dataset4,51. When one-to-one orthologs within C. elegans and P. pacificus are tested, there is lower 
expression of the orthologs that are X-linked, suggesting that X upregulation is absent88. An 
explanation for the difference in X upregulation status in the two analyses can be understood if X 
upregulation acts locally, instead of globally on tissues and dosage sensitive X-linked genes88. 
 
Mapping parameters include unique and non-unique mapping. Unique mapping aligns 
short reads to a single location in the genome and excludes reads that can map to multiple locations. 
Non-unique mapping allows for mapping of multi-mapping reads and paralogs, which are a result 
of gene duplication that occurs when a homolog is lost. Paralogous genes are important to study 
because gene duplication may be part of the mechanism of dosage compensation2. There are 
multiple genome annotation databases including RefSeq, Ensembl, Gencode, and the UCSC 
annotation database and the reference genome selected impacts mapping efficiency and gene 
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expression estimation89.  Jue et al found substantial variation in the estimation of RXE within the 
same human tissue type when using different genome annotations in the mapping program 
Cufflinks2. Library preparation methods vary in the initial selection. For example, Illumina-based 
library preparation selects for the poly-A tail of mature mRNA using oligodT magnetic beads and 
creates a 3’ bias. In addition, the Illumina TruSeq stranded mRNA library preparation kit allows 
for strand specific sequencing. Lastly, depth of sequencing coverage is essential in detecting lowly 
expressed genes, which contribute to accurate RXE values90.  
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CHAPTER 2 
2.1 X CHROMOSOME INACTIVATION 
 
X chromosome inactivation (XCI) involves the transcriptional silencing of one of the X 
chromosomes of either maternal or paternal origin in every diploid cell of female mammals57.  It 
is also a mechanism of dosage compensation that is unique to female placental mammals. The 
inactive X chromosome was first observed in 1949 as condensed heterochromatin only present in 
the nuclei of female somatic cells, which is now called the ‘Barr Body’91 (Figure 1).  The random 
form of X chromosome inactivation was first noted by Mary Lyon while studying coat color in 
mice, she observed that female mice that were heterozygous for an X-linked gene responsible for 
coat color displayed mosaic phenotypes of many different coat color patterns17. While XCI is 
random in mammalian somatic cells, it can either be random or imprinted in extra-embryonic 
tissues depending on the species. The imprinted form of X chromosome inactivation involves 
preferential silencing of the paternally inherited X chromosome, while the maternal X remains 
active58. The inactive X chromosome can be studied by fluorescence and immunostaining of 
several chromosome-wide markers92. The markers include X-inactive specific transcript (Xist) 
RNA coating, histone H3 lysine 27 methylation (H3K27me), and a chromatin modifying protein 
Eed92. In addition, the expression of Xist has been studied in mammalian species.   
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Figure 1. The black arrows point to the Barr body, the inactive X chromosome, within mouse 
nuclei.  From Kenney et al., 1965.  
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2.1.1 Random, imprinted, and skewed XCI 
 
Two distinct patterns of X chromosome inactivation occur in eutherian mammals, random 
XCI and imprinted XCI (Figure 1). Somatic cells of female eutherian mammals undergo random 
X chromosome inactivation in which one of the two X chromosomes in each cell is 
transcriptionally inactivated at random17. The inactivated X chromosome is condensed 
heterochromatin termed a Barr body and can be of either maternal or paternal origin91. A counting 
mechanism within the zygote first distinguishes the number of X chromosomes present in the cell 
and then the initiation mechanism selects an X chromosome to be inactivated. The multi-step 
process ensures a single, functional X chromosome in each adult diploid cell93. X chromosome 
inactivation is also apparent in human females with more than two copies of the X chromosome, 
as all X chromosomes except one are inactivated. Ohno described this as the “n-1” rule where an 
individual with n X chromosomes will have n-1 inactivated77. Random XCI is present in the 
embryonic and extra-embryonic tissues of the horse, mule, rabbit, and human21,94,95.  
 
Imprinted XCI is a nonrandom inactivation whereby the paternally inherited X 
chromosome is preferentially silenced and the maternally inherited X remains active58. Initiation 
of imprinted XCI begins in murine preimplantation embryos and is maintained in extra-embryonic 
tissues, most notably the placenta96. Placental tissues of cow97,98 and rat99 exhibit imprinted XCI. 
Random and imprinted XCI can be present in different cells from different embryonic layers within 
the same animal58,100,101,102. 
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 Skewed XCI is a disruption in normal X chromosome inactivation patterns. Inactivation 
predominantly occurs to either the paternally inherited X or the maternally inherited X103. Studies 
characterize skewed or non-random XCI as 75% of cells have the same inactive X58.   
 
 
2.1.2 Human and mouse XCI 
 
XCI is random in human somatic cells. X chromosome inactivation has been observed in 
human preimplantation embryos starting at the eight cell stage104. It has been unclear if XCI is 
random or imprinted in the human placenta101. A recent study of allele specific expression of SNPs 
on the X chromosome of human placenta samples revealed variable patterns of X chromosome 
inactivation organized into patches with the paternal or maternal X inactivated respectively94. 
 
 
XCI is random in mouse somatic cells. XCI follows an imprinted pattern in the mouse and 
rat placenta105,99. The trophectoderm and primitive endoderm display imprinted XCI and later 
become the placenta and yolk sac106. In the mouse, the paternal X chromosome is preferentially 
silenced and imprinted XCI is established at the four cell stage in embryonic preimplantation 
development107. In the inner cell mass of the blastocyst, the paternal X is reactivated and is 
followed by random X chromosome inactivation of the maternal or paternal X chromosome108. 
The inner cell mass gives rise to the embryo proper and later adult somatic tissues, which maintain 
random XCI109.  
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2.1.3 Bovine XCI 
 
XCI occurs in cattle97,110.  The gene Monoamine oxidase type A (MAOA) has been used 
to study XCI in cattle because it is an X-linked housekeeping gene in humans111 and mice112 that 
is subjected to XCI.  Xue et al first reported that Xist and MAOA were expressed in bovine kidney, 
brain, liver, heart, and spleen97. In bovine in vitro embryos, the MAOA gene displayed only 
maternal expression in the morula stage indicating the establishment of imprinted XCI. The 
establishment of imprinted XCI occurs later in the bovine than in the human and the mouse. 
Subsequently, the paternal X was reactivated in the inner cell mass of the blastocyst113.  
 
XCI is random in bovine somatic cells. Random X chromosome inactivation is re-
established between day 7 and day 14, corresponding to the blastocyst and early elongation 
stages114. In addition, two X-linked genes ubiquitin conjugating enzyme E2A (UBE2A) and 
spermidine/sperine N-acetyltransferase 1 (SAT1) were shown to partially escape XCI between 
these embryonic development stages114. In re-analysis of bovine blastocyst microarray expression 
data, higher expression of X-linked genes was observed in female blastocysts than male blastocysts 
indicating incomplete X chromosome inactivation and dosage compensation115.  
 
In cattle, different data are reported for the status of XCI in the placenta. In extra-embryonic 
tissue, the MAOA maternal allele is solely expressed97. Conversely, a recent study of the bovine 
intercotyledonary chorioallantois described random expression of the alleles of X-linked genes116. 
Day 15 bovine extraembryonic membranes showed biallelic Xist expression, while the 
trophectoderm cell line CT1 showed monoallelic Xist expression116.  
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2.1.4 Ovine XCI 
 
X chromosome inactivation is known to exist in sheep, but little is known about its onset 
and regulation. An inactive X chromosome was first observed in sheep fetal ovaries by radioactive 
staining and autoradiography as a heterochromatic chromosome located peripherally in 
comparison to the other chromosomes117. Studies have investigated the transcriptional activity of 
X-linked genes on the active X in ovine female embryos. It has been found that X-linked and Y-
linked genes are transcriptionally active in ovine preimplantation embryos starting at the 2-cell 
stage118. This is consistent with RT-PCR reports in mouse and human embryos119-122 .  
 
A study of Xist in sheep by Zhao et al found that Xist does not have tissue specific 
expression in female sheep, consistent with its expression from the inactive X in somatic cells. In 
brain, kidney, liver, spleen, lung, small intestine, ovary, muscle, and heart of two-day old lambs, 
Xist mRNA had little difference in expression123.  
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2.1.5 Genes escaping XCI 
 
Genes that escape X chromosome inactivation show expression from both the active and 
inactive X chromosomes124. An escaped gene has ≥10% expression from the allele that was 
inactivated125. Variation exists in the amount of expression from the inactive allele for individual 
genes and for the same gene in different tissues61. 10-15% of genes on the human X chromosome 
escape inactivation. The escaping genes are located in both the still recombining pseudoautosomal 
regions (PARS) and in the X-specific region in X-linked genes with an active homolog on the Y 
chromosome126. In somatic cells of mice, almost all X-linked genes remain inactivated and 3% 
escape inactivation127,128. Escape from XCI is also common in other placental mammals such as 
cows129.  There is a pattern in the distribution of escaping genes, possibly due to relative distance 
from Xist as most genes reveal clustering in the distal portion of the short arm of the X 
chromosome130. Studying genes that escape XCI helps to compare the difference in epigenetic 
marks and to better understand the mechanism of inactivation on the rest of the X chromosome.  
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CHAPTER 3 
3.1 EFFECT OF MATERNAL NUTRITION ON FETAL EPIGENETICS AND 
DEVELOPMENT 
 
While the fetal genome plays a large role in the growth and development of the fetus, 
increasing evidence supports a strong influence of the intrauterine environment on fetal 
development131. The phenomenon of fetal programming maintains that the intrauterine 
environment can induce changes in expression of the fetal genome and can permanently alter 
offspring physiology, structure, metabolic function, and growth postnatally132.  
 
Maternal nutrition can affect the intrauterine environment and epigenetically alter the fetal 
genome. Possible epigenetic modifications include DNA methylation and histone acetylation. 
Maternal nutrition studies in mice and rats have revealed that maternal diet can alter fetal gene 
expression through epigenetic modification, inducing physiological changes in the developing 
fetus133,134. Limited data exists pertaining to the effect of maternal nutrition on epigenetic and gene 
expression changes in sheep. In a recent study, pregnant ewe nutrition was found to change the 
expression of specific genes under strong epigenetic regulation known as imprinted genes in the 
sheep135.  
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3.1.1 Poor Maternal Nutrition 
 
Understanding the effect of poor maternal nutrition on sheep fetal development and the 
fetal genome is relevant to sheep production and metabolic disease136. Over and undernutrition of 
pregnant ewes are both representative of poor maternal nutrition during gestation. Because the 
sheep industry uses forage based systems137, pregnant ewes are subjected to both under and 
overnutrition based on the quality and quantity changes in forage in different seasons. Pregnant 
ewes have been used extensively as models for human pregnancy. Maternal-fetal interactions such 
as metabolic function and nutrient transport can be studied due to the ability to sample from fetal 
and maternal vasculature in sheep without the use of anesthesia31. In addition, researchers are also 
able to study nutritional programming, such as that induced in fetal growth restriction. In different 
stages of pregnancy, maternal nutrition can significantly alter offspring physiology, structure, and 
metabolism138. Maternal nutrition contributes to both fetal and placental growth139. Nutrient 
deficiency as a result of poor maternal nutrition during gestation has been shown to severely impair 
normal fetal and placental growth140  
 
Sheep research by the Govoni, Reed, and Zinn labs has focused on the effect of poor 
maternal nutrition on both the pregnant ewe and offspring by utilizing a control-fed (100% NRC), 
restricted-fed (60% NRC), and over-fed (140% NRC) treatment design141-146.  Ewes compensate 
for poor maternal nutrition by either reducing or increasing their own body weight. Pillai et al 
Restricted ewes and overfed ewes had decreased and increased body weight and body condition 
score respectively when compared to the control ewes at day 135 and birth (P≤ 0.05)146. Fetal body 
weight did not differ between maternal nutrition groups at day 45, day 90, or day 135146. Reed et 
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al found that ewe body weight at the end of gestation was reduced by 18.9% (18.3 ± 3.6 kg; P< 
0.01) in the restricted group and ewe body weight increased by 6.6% (119.7± 3.6 kg; P< 0.10) 
when compared to the control group (112.9± 3.6 kg)141.  
 
Maternal nutrition has been found to affect metabolic processes in sheep blood and fetal 
tissues. Hoffmann et al reported that overnutrition in ewes was found to affect metabolism in 3 
month old sheep by increasing circulating triglycerides indicating possible future metabolic 
disease147. The poor maternal nutrition studies by the aforementioned labs have also shown that 
poor maternal nutrition effects fat, muscle, and bone development prenatally and postnatally145. In 
addition, maternal nutrition can affect critical organ development such as the trend for increased 
heart size in sheep born to overfed mothers147. Pillai et al reported that no differences were found 
between maternal nutrition groups in fetal kidney and liver weight at day 90, day 135, and birth146. 
 
In a separate fetal sheep transcriptome study, muscle and adipose tissue were evaluated for 
the effect of maternal diet during mid-to-late gestation. Different maternal diet resulted in gene 
expression and energy metabolism changes in both tissues33. In twins and offspring from 
undernourished ewes, epigenetic modifications occur in sheep fetal hypothalamic pathways that 
regulate energy balance, altering these pathways increases the offspring’s chance of obesity and/or 
metabolic disease later in life136. The findings of maternal diet altering fetal epigenetics is of 
particular interest because XCI is an epigenetically regulated process.  
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3.2 SUMMARY 
 
Two mechanisms have evolved in mammals to balance the expression of X-linked genes 
between the sexes and to balance the expression ratio of the X chromosome to the autosomes. In 
Ohno’s hypothesis, X-linked gene expression is doubled in both males and females, successfully 
balancing with the autosome expression in males. While it is well characterized in Drosophila, 
this pattern has only recently been observed in mammalian species. In mammalian females, X-
chromosome inactivation (XCI) randomly and globally inactivates one of the X-chromosomes. 
Dosage compensation is known to be species, tissue, and developmental stage specific. This 
suggests the importance of studying dosage compensation and X chromosome inactivation in 
different species where research is limited such as the sheep. Sheep are a good model to investigate 
dosage compensation normally and under the effect of poor maternal nutrition. Poor maternal 
nutrition, both under and overnutrition are common based on the changes in quality and quantity 
of forage with the change of seasons. In humans, obesity and type 2 diabetes are late onset diseases 
that occur in response to earlier nutritional conditions that effect epigenetic marks such as histone 
tail modification and DNA methylation148. It has also been shown that supplementing or restricting 
folate, choline, or methionine in the maternal diet can affect DNA methylation pattern 
establishment in offspring149,150. Maternal nutrition can influence epigenetic modifications of the 
fetal genome and may result in changes in expression of X-linked genes.  
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3.3 OBJECTIVES 
 
Dosage compensation and X chromosome inactivation have been studied thoroughly in 
mice and humans, but research in domestic species, livestock in particular, has lagged behind. 
Proper dosage compensation and XCI are needed for viable offspring and disruptions are 
associated with disease. With the advancement of RNA sequencing technology, more 
transcriptomic studies can be performed in domestic species to uncover the complex epigenetic 
mechanisms. Very few RNA sequencing experiments have been conducted in the sheep. Here we 
present the first RNA-seq experiment evaluating sex chromosome dosage compensation. In 
combination with the data of this study, two additional RNA-seq datasets (PRJEB6169) and 
(PRJNA254105) were added to achieve a more global view of dosage compensation in the 
sheep151,152. In addition, while it is known that maternal diet can influence epigenetic changes in 
the developing fetus, the effect of maternal diet on dosage compensation is unknown. By 
investigating the effect of maternal under and overnutrition on X-linked genes, we hope to uncover 
more insight into the compensatory nature of dosage compensation under an environmental 
stressor.   
 
The first objective of this study was to characterize global dosage compensation in the 
sheep using data from this study and additional RNA-seq datasets (PRJEB6169) and 
(PRJNA254105). In the three combined datasets, we were able to analyze sheep dosage 
compensation in fetal brain, kidney, lung, day 14 embryos (PRJNA254105), adult and juvenile 
heart, liver, muscle, and rumen in both males and females (PRJEB6169). Specific brain tissue and 
female and male specific tissues (PRJEB6169) were also evaluated. We hypothesized that dosage 
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compensation in the sheep would be incomplete, similar to that of the cow115. The second objective 
was to determine the effects of maternal control, restricted, and overfed diets on the expression of 
X-linked genes in fetal tissues at 135 days of gestation. We hypothesized that maternal diet may 
influence the X-linked genes that are expressed and their expression level in ovine fetuses.  
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3.4 MATERIALS AND METHODS 
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3.4.1 Animals 
 
All animal protocols141-147 were reviewed and approved by the University of Connecticut 
Institutional Animal Care and Use Committee. Animal breeding, feeding and care, necropsy, and 
sample collection were performed by the labs of Dr. Govoni, Dr. Reed, and Dr. Zinn. The research 
animals, fifteeen western white faced ewes and four line bred Dorset rams were purchased and 
shipped from Midwest farms and Indiana respectively. The relatedness of the rams is included in 
a pedigree chart (Figure 1) and the relatedness of the ewes is unknown. Estrous synchronization153 
of ewes was accomplished with progesterone controlled intravaginal drug release devices (Pfizer 
Animal Health; New York, NY, USA) and Lutaylase (Pfizer Animal Health). Ewes were bred live 
cover to one of the Dorset rams as previously described141-147. Pregnancy was confirmed by 
ultrasound on day 20 of gestation if a ewe was not re-marked by a ram, day 0 represents the initial 
marking of the ewe by the ram. On day 30 of gestation, pregnant ewes were individually housed 
and randomly assigned to control (100% NRC requirement), restricted (60%), or overfed (140%) 
diets calculated by the National Research Council requirement for total digestible nutrients for a 
ewe pregnant with twins141,154. Ewes were weighed weekly to track body weight gain and to adjust 
diets throughout the pregnancy. The ewes remained on their respective diets until day 135 of 
gestation, when they were euthanized and necropsied to collect fetal tissues.  
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3.4.2 Fetal brain, kidney, and lung sample collection and selection 
  
 Samples were collected and provided by the labs of Dr. Govoni, Dr. Reed, and Dr. Zinn.  
Within each treatment group, brain, kidney, and lung were collected from each fetus. The control 
group consisted of four ewes and eight fetuses (8 brain, 8 kidney, and 8 lung samples). The 
restricted group consisted of seven ewes and thirteen fetuses (13 brain, 13 kidney, and 13 lung 
samples). The overfed group consisted of six ewes and ten fetuses (10 brain, 10 kidney, and 10 
lung samples) (Table 1).  Samples were further selected for this study genetically representing 
each ram present in each nutritional treatment and selecting singletons over twins and triplets to 
increase the genetic diversity.  
 
Brain, lung, and kidney were selected from seven control fetuses (3 females and 4 males), four 
restricted fetuses (1 female and 3 males), four overfed fetuses (3 females and 1 male) (Table 2). 
We included an increased number of fetuses in the control group to increase the power of studying 
normal dosage compensation in the sheep. Tissues were flash frozen in liquid nitrogen and were 
stored at -80°C until RNA extraction was performed.  
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Figure 1. Ram Pedigree chart.  The Pedigree shows the relatedness of the rams used in the 
study. Ram 2 & Ram 4 are half siblings with the same father 73337 and different mothers, 
Ram 1 & 2 have the same grandfather, Ram 3 & Ram 4 have the same maternal grandfather, 
Ram 1’s mother is half sibling to Ram 2’s father and mother, and Ram 3’s mother is half 
sibling to Ram 4’s mother. 
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Table 1 Sample Selection  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
44 
 
Table 2 Total Sample Collection  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
* one fetus sampled, 2nd mummy. F=fetus 
 
 
 
 
 
Treatment 
EWE 
ID 
Ram 
ID 
Number of 
offspring Kidney Brain Lung 
Control 
 
  61* 4   2* F1 F1 F1 
75 3 3 F1, F2, F3 F1, F2, F3 F1, F2, F3 
79 4 2 F1, F2  F1, F2 F1, F2 
107 4 2 F1, F2 F1, F2 F1, F2 
Over 
 
10 4 1 F1 F1 F1 
56 3 2 F1, F2 F1, F2 F1, F2 
63 4 2 F1, F2 F1, F2 F1, F2 
  66* 1   2* F1 F1 F1 
89 1 2 F1, F2 F1, F2 F1, F2 
93 4 2 F1, F2 F1, F2 F1, F2 
Restricted 
 
3 1 3 F1, F2, F3 F1, F2, F3 F1, F2, F3 
18 3 1 F1 F1 F1 
69 4 2 F1, F2 F1, F2 F1, F2 
77 1 1 F1 F1 F1 
94 3 2 F1, F2 F1, F2 F1, F2 
101 3 2 F1, F2 F1, F2 F1, F2 
118 2 2 F1, F2 F1, F2 F1, F2 
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3.4.3 RNA isolation and quality control 
 
 RNA was extracted from fetal brain, kidney, and lung using TRIzol (Invitrogen, Grand 
Island, NY) according to the manufacturer’s instructions. The homogenization procedure was 
optimized at a frequency of 30 Hz for 3-4 minutes using the TissueLyser II homogenizer (Qiagen 
Sample and Assays Technology, USA). RNA samples were purified using the Qiagen RNeasy kit 
(Qiagen, Valencia, CA, USA) and a Dnase treatment (Qiagen, Valencia, CA, USA) was applied. 
RNA quality was examined by spectrophotometry and with the Agilent Total RNA Nano kit 
(Agilent Technologies, Santa Clara, CA). All samples had RNA Integrity Numbers (RINs) greater 
than or equal to 7 (RIN ≥ 7) (Table 3). The concentration of total RNA used in library preparation 
was calculated using a Qubit 2.0 Fluorometer (Thermo Fisher scientific; Waltham, MA, USA) 
(Table 3).  
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            Table 3 RNA Quality and Quantity 
Tissue Treatment Sample ID RIN 260/280 
 Qubit RNA 
 concentration (ng/μl) 
           
Brain 
Control 
1 8.3 2.20 1176 
2 8.7 2.15 230 
3 7.0 2.23 85.8 
4 8.1 2.22 472 
5 8.8 2.14 1170 
6 7.0 2.14 576 
7 8.0 2.14 1158 
Restricted 
1 8.3 2.19 724 
2 7.5 2.14 252 
3 8.4 2.13 103 
4 8.1 2.16 858 
Overfed 
1 8.2 2.18 720 
2 7.4 2.19 220 
3 8.5 2.19 468 
4 9.0 2.18 1266 
Lung 
Control 
1 9.5 2.18 796 
2 9.4 2.14 396 
3 9.4 2.18 510 
4 9.0 2.17 464 
5 10 2.14 573 
6 9.7 2.14 1860 
7 9.9 2.14 1920 
Restricted 
1 8.2 2.16 1448 
2 8.9 2.14 422 
3 8.8 2.13 384 
4 9.4 2.12 342 
Overfed 
1 9.0 2.17 988 
2 9.1 2.18 540 
3 9.3 2.19 488 
4 9.1 2.18 684 
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Tissue Treatment Sample ID RIN 260/280 
 Qubit RNA 
concentration 
          (ng/μl) 
Kidney 
Control 
1 8.9 2.12 450 
2 7.3 2.15 1264 
3 9.3 2.08 736 
4 7.8 2.11 1160 
5 9.1 2.14 1470 
6 7.3 2.14 1092 
7 8.3 2.14 2226 
Restricted 
1 8.8 2.04 2412 
2 9.1 2.10 1996 
3 7.5 2.18 1280 
4 9.3 2.16 330 
Overfed 
1 9.2 2.10 494 
2 8.4 2.10 524 
3 8.9 2.15 648 
4 7.8 2.20 1224 
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3.4.4 Library preparation, quality control, and quantification 
 
 
 An average input of 2 μg of total RNA/sample was used to prepare 45 cDNA libraries for 
sequencing following the manufacturer’s instructions by the Illumina TruSeq mRNA library prep 
kit. This protocol involves purification of mRNA by poly-T oligo-attached magnetic beads, 
fragmentation, priming with random hexamers, incorporation of dUTTP during second strand 
synthesis for strand specific sequencing, and adapter ligation. Library quantification was 
performed using the KAPA qPCR kit and the Agilent DNA 1000 kit (Agilent Technologies, Santa 
Clara, CA) was used with the Agilent Bioanalyzer to obtain average library lengths and to ensure 
the absence of adapter dimerization (Table 4).  
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Table 4 Library Preparation  
           
Tissue Treatment 
Sample 
ID 
Total RNA 
input for 
library 
prep 
nanodrop 
cDNA library 
concentration 
Bioanalyzer 
average library 
lengths  
KAPA qRT-
PCR Average 
Stock Library 
Concentration  
      (ng) (ng/ul) (bp) (nM) 
Brain 
Control 
1 2352 84.1 247 348 
2 1380 66.2 266 254 
3 1030 66.8 240 418.4 
4 2832 68.8 255 699.3 
5 2340 86.7 257 194.1 
6 2304 78.5 261 280.3 
7 2316 78.8 246 361.7 
Restricted 
1 3982 90.1 268 551.7 
2 1512 71.6 247 489.5 
3 1236 86.2 251 577 
4 2145 84.6 248 433.5 
Overfed 
1 2160 82.9 247 330.5 
2 1320 71.7 252 565 
3 2808 90.7 245 657.8 
4 2279 84.0 250 294.2 
Lung 
Control 
1 2388 79.2 240 472.3 
2 2376 86.2 243 400 
3 3060 89.1 277 445 
4 2088 70.4 274 302 
5 2292 86.3 252 299 
6 2232 82.3 275 228 
7 2304 78.9 275 328 
Restricted 
1 2172 56.1 268 285 
2 2532 70.4 245 298 
3 2304 85.7 257 573.6 
4 2052 87.1 247 661 
Overfed 
1 2174 80.1 264 310.8 
2 3240 85.3 243 263.4 
3 2928 79.6 255 563.3 
4 2052 78.0 244 247.2 
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Tissue Treatment 
Sample 
ID 
Total RNA 
input for 
library 
prep 
nanodrop 
cDNA library 
concentration 
Bioanalyzer 
average library 
lengths  
KAPA qRT-
PCR Average 
Stock Library 
Concentration  
      (ng) (ng/ul) (bp) (nM) 
Kidney 
Control 
1 2700 100.2 233 2229.3 
2 2275 76.4 262 403 
3 2208 89.5 242 372.3 
4 2320 83.4 245 273 
5 2205 87.0 285 313.3 
6 2190 79.9 267 393.9 
7 2226 82.2 268 356 
Restricted 
1 2412 49.0 220 363.1 
2 2395 61.1 242 426.2 
3 2304 86.6 246 324 
4 1980 89.8 251 2065.7 
Overfed 
1 2470 92.7 244 1454.8 
2 2096 50.9 267 344 
3 3888 82.2 259 1276.8 
4 2203 82.9 261 385 
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3.4.5 RNA sequencing 
 
Barcoding adapters were added in the processing of the 45 cDNA libraries, they were 
pooled at a concentration of 4 nM, and libraries were sequenced on the Illumina NextSeq 500 
Platform at the Center for Genome Innovation, University of Connecticut. The RNA-seq libraries 
were sequenced with 2 ×75 bp paired-end reads on the NextSeq500 in three sequencing runs and 
one percent PhiX DNA was spiked in as an internal control each time. A total of 1160, 576, and 
413 million raw sequencing reads passing filtering were obtained for sequencing runs 1, 2, and 3 
respectively. Overall, we obtained 2149 million raw sequencing reads passing filtering from three 
sequencing runs of 45 fetal tissue samples.  
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Table 5 RNA Sequencing Runs and Adapters 
 
 
 
 
RNA-
Seq 
Run 
number Tissue Treatment  Sample ID 
Adapter 
number 
Adapter 
sequence 
Mean % 
Reads  
Identified 
(Post 
Filtering) 
% Mapped 
Reads 
Number of 
Mapped 
Reads  
Run 1 
Brain 
Control 
1 11 GGCTAC(A) 3.8 0.89  17,261,538  
2 7 CAGATC(A) 1.5 0.90  6,629,510  
3 6 GCCAAT(A) 3.1 0.90  15,055,094  
4 13 AGTCAA(C) 2.0 0.91  9,932,518  
5 22 CGTACG(T) 8.2 0.90  40,040,450  
6 23 GAGTGG(A) 5.0 0.90  24,500,963  
7 25 ACTGAT(A) 4.1 0.90  20,089,481  
Restricted 
1 12 CTTGTA(A) 3.0 0.91  14,836,023  
2 14 AGTTCC(G) 3.0 0.91  14,979,444  
3 3 TTAGGC(A) 2.2 0.91  10,926,581  
4 10 TAGCTT(A) 3.7 0.91  17,921,173  
Overfed 
1 9 GATCAG(A) 4.5 0.90  21,904,593  
2 4 TGACCA(A) 2.2 0.91  11,086,560  
3 1 ATCACG(A) 2.6 0.91  12,564,537  
4 8 ACTTGA(A) 5.7 0.91  27,966,870  
Lung 
Control 
1 5 ACAGTG(A) 3.4 0.90  16,897,583  
2 27 ATTCCT(T) 4.1 0.90  20,199,107  
3 2 CGATGT(A) 3.8 0.90  18,491,810  
4 20 GTGGCC(T) 4.8 0.90  23,499,521  
5 15 ATGTCA(G) 5.4 0.90  26,421,784  
6 16 CCGTCC(C) 6.2 0.89  29,926,965  
7 19 GTGAAA(C) 5.0 0.90  24,366,852  
Restricted 2 21 GTTTCG(G) 6.9 0.90  33,525,561  
4 18 GTCCGC(A) 2.8 0.90  13,964,369  
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RNA-
Seq Run 
number Tissue Treatment  
Sample 
ID 
Adapter 
number 
Adapter 
sequence 
Mean % 
Reads  
Identified 
(Post 
Filtering) 
% 
Mapped 
Reads 
Number 
of 
Mapped 
Reads 
Run 2 
Lung 
Overfed 
1 20 GTGGCC(T) 12.9 0.89 
 
60,526,905  
2 25 ACTGAT(A) 4.6 0.91 
 
22,129,781  
3 22 CGTACG(T) 3.0 0.91 
 
14,345,916  
4 16 CCGTCC(C) 6.5 0.90 
 
30,242,283  
Restricted 1 21 GTTTCG(G) 5.4 0.90 
 
25,508,281  
3 23 GAGTGG(A) 2.9 0.90 
 
13,539,473  
Kidney 
Overfed 
1 19 GTGAAA(C) 1.6 0.91  7,591,885  
2 15 ATGTCA(G) 4.6 0.91 
 
21,765,983  
3 13 AGTCAA(C) 1.5 0.91  7,026,844  
4 18 GTCCGC(A) 3.8 0.91 
 
17,920,199  
Restricted 3 14 AGTTCC(G) 5.1 0.90 
 
24,124,589  
Run 3 Kidney 
Control 
1 21 GTTTCG(G) 1.0 0.91  4,836,961  
2 16 CCGTCC(C) 3.9 0.90 
 
17,858,838  
3 23 GAGTGG(A) 4.4 0.91 
 
20,386,772  
4 25 ACTGAT(A) 5.2 0.90 
 
24,242,852  
5 15 ATGTCA(G) 5.4 0.91 
 
25,146,483  
6 18 GTCCGC(A) 3.8 0.90 
 
17,692,978  
7 19 GTGAAA(C) 4.5 0.90 
 
20,656,829  
Restricted 
1 22 CGTACG(T) 4.5 0.91 
 
20,732,144  
2 27 ATTCCT(T) 4.1 0.90 
 
18,835,286  
4 20 GTGGCC(T) 1.1 0.91  4,992,172  
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3.4.6 Additional RNA-seq datasets 
 
To analyze X dosage compensation across tissue types, female and male specific tissues, 
and embryos, two additional RNA-seq datasets were downloaded from Sequence Read Archive 
(SRA) (http://www.ncbi.nlm.nih.gov/sra) under the accession numbers PRJNA254105152 and 
PRJEB6169151. The additional datasets include day 14 embryos (PRJNA254105), adult and 
juvenile heart, brain, liver, biceps, rumen, and female and male specific tissues (PRJEB6169). 
Female specific tissues include cervix, ovarian follicles, ovary, uterus, and corpus luteum. Male 
specific tissues include testes and epididymis. To normalize within each dataset, the mRNA level 
of each gene was estimated by transformed transcripts per kilobase million (TPM) and was 
quantified using IsoEM (version 1.1.4). 
 
3.4.7 RNA-seq data trimming and mapping 
 
 Sequence adapter and quality trimming were done using Sickle v1.33 with the parameters 
Q score ≥ 30 and length ≥ 20 (-q30, -l20).  After filtering, read quality was checked using FastQC 
v0.11.3.. Filtered RNA-seq reads from fetal day 135 tissues were aligned to the sheep reference 
genome Oar_v4.0  using Hisat2 v2.0.5155 (Table 5).  
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3.4.8 RNA-seq data assembly and Dosage compensation calculation 
 
Aligned reads for each tissue from our study and two sheep online public datasets were 
assembled using IsoEM v1.1.4 to estimate gene expression in transcripts per kilobase per million 
(TPM). Only genes with TPM>1 were selected for later analysis, and were later log 2-transformed. 
Gene expression chromosome-wide distributions for 20,549 genes were isolated by chromosome 
and then plotted in R. The relative X expression (RXE) was calculated for X-linked genes (x) and 
autosomal genes (a) by following formula: 
𝑅𝑅𝑅𝑅𝑅𝑅 = log2 �𝑥𝑥𝑎𝑎� = log2 𝑥𝑥 − log2 𝑎𝑎 
An RXE greater than or equal to 0 represents up-regulation of X and dosage compensation. An 
RXE between 0 and -1 indicates X up-regulation, but incomplete dosage compensation.  When 
RXE is equal to -1 dosage compensation is nonexistent.  
 
3.4.1.9 Gene ontology of X-linked genes 
 
A Gene Ontology (GO) classification was conducted on the combined list of expressed  X-
linked genes found in sheep brain, lung, and kidney for all treatments using DAVID 6.8 156,157. 
Specifically, a functional annotation enrichment analysis revealed GO terms and major functional 
categories. Major Gene Ontology terms are presented with Benjamani-Hochberg adjusted P-
values.  
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3.5 RESULTS 
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3.5.1 Dosage compensation in sheep 
 
Here we present the first comprehensive study of dosage compensation in the sheep using 
RNA sequencing data of day 135 fetal sheep somatic tissues. The addition of two other RNA seq 
datasets allows for a more precise study of dosage compensation in male and female specific 
organs and within more varied somatic tissues. Relative X expression (RXE) is calculated for all 
tissues to standardize and compare dosage compensation.  
 
 
3.5.2 Dosage compensation in ovine major organs 
 
The major organs: heart, liver, muscle, rumen, placenta, and day 14 embryos displayed 
incomplete dosage compensation. The mean RXE values had a range of -0.19 to -0.05 in the major 
organs evaluated, with an overall average RXE of -0.12 respectively (Figure 1A). No significant 
difference was observed between male and female organ tissues. Dosage appears to be more highly 
compensated in the brain.  Average RXE had a range of -0.12 to 0.16 in brain cerebrum, 
cerebellum, hypothalamus, and pituitary (Figure 1B). All brain tissues, with the exception of 
cerebellum displayed complete dosage compensation. Compared to the other major organs studied, 
brain had the highest overall average RXE of 0.01.  
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3.5.3 Dosage compensation in ovine female specific tissues 
 
Incomplete dosage compensation was observed in juvenile and adult female specific 
cervix, ovarian follicles, ovary, uterus, and corpus luteum. The overall RXE varied slightly 
between juvenile and adult female tissues with an average RXE of -0.19 for juvenile tissues and 
an average RXE of -0.15 for adult tissues respectively (Figure 2A). The combined juvenile and 
adult female specific tissues ranged in average RXE from -0.32 to -0.03.  
 
3.5.4 Dosage compensation in ovine male specific tissues 
 
Two male specific tissues, testes and epididymis were studied. An interesting pattern was 
observed, as there was low dosage compensation in the testes at an average RXE of -0.84 and high 
compensation of 0.32 in the epididymis (Figure 2B). The average RXE of the two male specific 
tissues was -0.33. This pattern has been observed in drosophila, mouse, human, and rat testes26.  
 
3.5.5 Dosage compensation and maternal nutrition 
 
Dosage compensation was investigated for changes due to maternal over or undernutrition. 
Fetal control tissues, both male and female, displayed incomplete dosage compensation. The mean 
RXE values had a range of -0.14 to -0.06 in brain, lung, and kidney, with an overall average RXE 
of -0.10 respectively (Figure 3A). Fetal tissues from the overfed treatment displayed incomplete 
dosage compensation. Mean RXE values ranged from -0.09 to -0.07 in the three tissues. Overall 
average X: autosome expression ratio of overfed fetal tissues was -0.08 (Figure 3B). Fetal tissues 
from the restricted treatment displayed incomplete dosage compensation. Mean RXE values 
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ranged from -0.13 to -0.09 in the three tissues. Overall average X: autosome expression ratio of 
restricted fetal tissues was -0.11 (Figure 3C). The pattern of dosage compensation remained fairly 
consistent between treatment groups. 
 
 
3.5.6 X-linked genes in ovine somatic tissues 
 
The mean number of expressed X-linked genes was calculated separately for each tissue 
type in the control, restricted, and overfed groups (Table 1). This allows for an even comparison 
between the effect of maternal nutrition on the number of X-linked genes expressed in a single 
tissue. The mean number of expressed X-linked genes for the control group was 459 ± 3.8 in the 
brain, 442.7 ± 2.7 in the kidney, and 429.3 ± 1.0 in the lung. Significance was tested using the 
Kruskal-Wallis one-way ANOVA in the IBM SPSS software. The mean did not change 
significantly based on maternal nutrition. The ten most highly expressed X-linked genes were 
investigated in female and male control brain, kidney, and lung. X-linked genes with the highest 
expression in fetal brain, lung, and kidney displayed tissue specificity as only four genes were 
consistent among all three tissues.  
 
The four genes in common were thymosin beta 4, X-linked (TMSB4X), ribosomal protein 
L10 (RPL10), ribosomal protein L39 (RPL39), and ribosomal protein S4, X-linked (RPS4X). 
Large gene overlap between the three treatments revealed that these genes are highly expressed 
irrespective of treatment. TMSB4X, RPL10, and RPS4X had the highest expression in the lung 
while RPL39 had the highest expression in both the lung and kidney. Thymosin beta 4, X-linked 
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(TMSB4X) is in a highly conserved class of small proteins found in immune tissues, where it 
functions in wound healing, anti-inflammation, cell survival, and apoptosis158. Rengaraj et al 
observed that rat TMSB4X is expressed at an intermediate level in brain and kidney and chicken 
TMSB4X is expressed at almost equal measure in the brain and is 1.76-fold lower in the kidney158. 
Ribosomal protein L10 (RPL10) encodes a ribosomal protein that is part of the large ribosomal 
subunit and participates in ribosome function and biogenesis159. RPL10 has been studied in bovine 
blastocyst formation and it was found that RPL10 expression is higher in vivo at the 8-cell stage 
than in vitro160. Ribosomal protein L39 (RPL39) also encodes a ribosomal protein that is part of 
the large ribosomal subunit. Mutations in RPL39 lead to the initiation and metastasis of tumors, 
which have been studied in breast and lung cancer161. Ribosomal protein S4, X-linked (RPS4X) 
encodes the ribosomal protein S4 that is part of the small ribosomal subunit. This protein is also 
encoded by ribosomal protein S4, Y-linked (RPS4Y). RPS4X has been observed to have similar 
expression in bovine somatic cell nuclear transfer (SCNT) embryos and SCNT freemartin 
embryos162. 
 
In control female and male brain, the top ten highly expressed X-linked genes were 
consistent, but had different expression measured in TPM based on fetal sex (Figure 4). The gene 
PLP1 (Proteolipid Protein 1) had the highest expression in the brain at 2422.5 ± 362.2 TPM and 
2117.8 ± 1044.5 respectively for males and females. NGFRAP1 (Nerve Growth Factor Receptor-
Associated Protein 1) aka BEX3 (Brain Expressed X-Linked 3) had the lowest expression at 653.2 
± 84.7 TPM and 607.2 ± 8.2 TPM respectively for males and females. The genes GDI1 (GDP 
Dissociation Inhibitor 1), TSPAN7 (Tetraspanin 7), GPM6B (Glycoprotein M6B), and SYP 
(Synaptophysin) were also among the most highly expressed.  
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In control female and male kidney, seven of the top ten highly expressed X-linked genes 
were consistent, but had different expression measured in TPM based on fetal sex (Figure 5). 
Female control kidney included the genes CAPN6 (Calpain 6), S100G (S100 Calcium Binding 
Protein G), and SSR4 (Signal Sequence Receptor Subunit 4), while male control kidney included 
the genes PGRMC1 (Progesterone Receptor Membrane Component 1), BGN (Biglycan), and 
PGK1 (Phosphoglycerate Kinase 1). The gene RPL10 had the highest expression in the kidney at 
3212.3 ± 281.3 TPM and 2977 ± 206.5 TPM respectively for males and females. PGK1 had the 
lowest expression in males at 340.2 ± 52.8 TPM and SSR4 had the lowest expression in females 
at 387.5 ± 18 TPM. The genes RPL36A (Ribosomal Protein L36a), SAT1 (Spermidine/Spermine 
N1-Acetyltransferase 1), GPC3 (Glypican 3) were also among the most highly expressed.  
 
In control female and male lung, nine of the top ten highly expressed X-linked genes were 
consistent, but had different expression measured in TPM based on fetal sex (Figure 6). Female 
control lung included the gene GPC3 (Glypican 3), while male control lung included the gene 
FLNA (Filamin A). In addition, the gene MSN (Moesin) was not among the top ten highly 
expressed genes in brain and kidney. The gene RPL10 had the highest expression in the lung at 
3443 ± 180.8 TPM and 4068 ± 371.7 TPM respectively for males and females. FLNA had the 
lowest expression in males at 400 ± 20 TPM and GPC3 had the lowest expression in females at 
387.2 ± 23.2 TPM. 
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3.5.7 Gene Ontology analysis of X-linked genes 
 
The total number of unique expressed X-linked genes in control, restricted, and overfed 
fetal day 135 brain, kidney, and lung was found by compiling files of all expressed X-linked genes 
in each tissue sample with a TPM>1 and filtering out the duplicates. This yielded a combined list 
of 513 expressed X-linked genes in brain, kidney, and lung from all of the treatment groups that 
were used for gene ontology analysis. The gene ontology terms, negative regulation of microtubule 
depolymerization and synapse had the lowest P-values of 7.43E-03and 9.70E-03 respectively. The 
largest gene counts were attributed to zinc binding, intracellular, chromatin binding, and nucleotide 
binding. Out of the 513 expressed X-linked genes in this study, 14 genes reside in the ruminant 
pseudoautosomal region (Figure 7). The genes are P2RY8, DHRSX, ZBED1, CD99, XG, GYG2, 
ARSE, MXRA5, PRKX, NLGN4X, STS, PNPLA4, TBL1X, and GPR143. 
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3.6 DISCUSSION 
 
To our knowledge, this is the first comprehensive study of dosage compensation in the 
sheep. We conclude that dosage compensation is present, but incomplete in sheep somatic tissues. 
This is consistent with dosage compensation studies in cattle that have reported incomplete dosage 
compensation in somatic tissues163,164. Ovine male and female major organs had similar RXE 
values. In addition, the average overall RXE did not differ much between the three nutritional 
treatment groups. Dosage compensation was not able to be investigated in the sheep placenta as 
caruncle and cotyledon tissues were difficult to separate completely. 
 
We observed low dosage compensation in the male specific testes and high dosage 
compensation in the epididymis. This is consistent with the pattern of low dosage compensation 
in Drosophila testes and higher dosage compensation in the germline as well as with the low X:A 
ratio in mouse, rat, and human testes and spermatids26. Brain was determined to have the highest 
overall RXE compared to other somatic tissues and this has also been observed in Drosophila 
brain62 and in mammals26, specifically human, mouse, old world monkeys, opossum, platypus, and 
chicken4. Overall, a pattern of incomplete dosage compensation was observed in somatic tissues 
of day 135 fetal brain, lung, and kidney. Among the treatment groups, we calculated the highest 
average X: autosome expression ratio of -0.08 for brain, followed by -0.09 for kidney, and -0.11 
for lung. The average RXE for all treatment groups ranged from -0.11 to -0.08 respectively.  
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The most highly expressed X-linked genes in fetal day 135 brain, kidney, and lung were 
found to differ in expression between males and females in the control group. Thymosin beta 4, 
X-linked (TMSB4X), ribosomal protein L10 (RPL10), ribosomal protein L39 (RPL39), and 
ribosomal protein S4, X-linked (RPS4X) were common in brain, kidney, and lung. TMSB4X, 
RPL10, and RPS4X had the highest expression in the lung while RPL39 had the highest expression 
in both the lung and kidney. 
 
Our gene ontology results were consistent with other studies in sheep. A study of SNPs on 
the X chromosome in sheep important to artificial selection found gene ontology related to 
molecular functions, cellular components, and biological processes28. X chromosome genes found 
in sheep are linked to immune function, which has also been found in selection signatures in 
pigs165. Out of the combined list of 513 expressed X-linked genes in fetal day 135 brain, kidney, 
and lung, 14 genes reside in the pseudoautosomal region. These genes had low expression ranging 
from 1 TPM to 50 TPM. X-linked genes in the pseudoautosomal region are known as dosage-
insensitive genes because they have a homologous gene on Y chromosome. Our study of X 
chromosome dosage compensation reveals incomplete dosage compensation in sheep somatic 
tissues. Potential future work to improve the current study includes an increased sample size and 
additional nutritional factors that can influence epigenetic mechanisms such as altering the protein 
content in the pregnant ewe’s diet. Future studies into dosage compensation of other tissues, X-
linked genes in the ruminant pseudoautosomal region and X-specific regions are warranted.   
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Table 1. Mean number of expressed X-linked genes in control, restricted, and overfed day 
135 fetal tissues 
  
 
 
 
 
 
     
  Treatment   
 Control Restricted Overfed P-value 
Brain 459±3.8 453.5±2.2 455.3±3.2 0.66 
Kidney 442.7±2.7 444.3±1.5 439.5±2.7 0.37 
Lung 429.3±1.0 427.3±0.6 427±3.7 0.66 
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GO terms Count 
% of 
Genes P-value Genes 
negative regulation of microtubule depolymerization 4 0.8 7.43E-03 FGF13, MID1IP1, MID1, HDAC6 
synapse 7 1.4 9.70E-03 GABRE, SLC9A6, GABRA3, NLGN4X, CASK, GLRA4, GABRQ 
siRNA binding 3 0.6 1.99E-02 FMR1, MECP2, TLR7 
sulfuric ester hydrolase activity 3 0.6 2.51E-02 STS, ARSE, IDS 
cristae formation 3 0.6 2.76E-02 APOOL, TAZ, APOO 
nucleoside metabolic process 3 0.6 2.76E-02 UPRT, PRPS2, PRPS1 
intracellular 27 5.3 3.02E-02 
SAT1, AVPR2, ZNF81, ASB11, ZNF75D, NXT2, AGTR2, ZNF182, PAK3, ERAS, DOCK11, 
GDI1, MCF2, ARHGEF6, BMX, MID1, RAB33A, ASB9, ZNF157, RPS6KA3, CD40LG, 
ARAF, SYTL5, NRK, HEPH, ARL13A, ZNF41 
oxidoreductase activity 7 1.4 4.16E-02 GDI1, CYBB, MAOA, MAOB, F8, CHM, DHRSX 
chromatin binding 13 2.5 4.28E-02 
AR, MED12, POLA1, MECP2, HMGN5, RBMX, CITED1, ARX, ATRX, NONO, SMC1A, 
TBL1X, PHF8 
receptor activity 5 1.0 5.52E-02 IGSF1, ATP6AP2, MED12, AMOT, MED14 
positive regulation of exocytosis 3 0.6 5.54E-02 RAB9A, ATP6AP1, SYTL4 
positive regulation of synapse assembly 5 1.0 5.72E-02 SLITRK2, SLITRK4, SRPX2, MECP2, NLGN3 
ribonucleoside monophosphate biosynthetic process 2 0.4 5.86E-02 PRPS2, PRPS1 
nucleotide binding 13 2.5 6.05E-02 
RBM41, CSTF2, RBM3, PABPC5, POLA1, RBMX, NONO, ATP7A, HNRNPH2, UPF3B, 
HTATSF1, ZRSR2, RBM10 
positive regulation of interleukin-4 production 3 0.6 6.34E-02 CD40LG, FOXP3, SASH3 
catalytic activity 6 1.2 6.91E-02 PHKA2, SYN1, PHKA1, TKTL1, PCYT1B, ACSL4 
growth cone 4 0.8 6.95E-02 FRMD7, USP9X, FMR1, FGF13 
axon extension 3 0.6 7.18E-02 SLC9A6, USP9X, DCX 
cytokine receptor activity 3 0.6 7.35E-02 IL2RG, IL13RA1, IL13RA2 
zinc ion binding 33 6.4 7.96E-02 
ZMAT1, APEX2, XIAP, FHL1, CA5B, RLIM, GATA1, USP27X, JADE3, MORC4, DMD, 
ZNF185, ZDHHC9, RNF128, RGN, LONRF3, KDM5C, AR, ZMYM3, SUV39H1, MID1, 
TAB3, MID2, ZDHHC15, PJA1, TEX13B, DRP2, PRICKLE3, ITGB1BP2, PHF8, RNF113A, 
HDAC6, PHF6 
Rho guanyl-nucleotide exchange factor activity 5 1.0 8.06E-02 FGD1, MCF2, ARHGEF6, ARHGEF9, DOCK11 
protein serine/threonine kinase activity 10 1.9 8.08E-02 SRPK3, IRAK1, RPS6KA6, RPS6KA3, PAK3, PDK3, ARAF, WNK3, PIM2, CDK16 
signal transduction 10 1.9 8.41E-02 
ARHGAP4, ARHGAP6, IGSF1, TENM1, STARD8, OPHN1, ARHGAP36, IL1RAPL2, OCRL, 
IL1RAPL1 
regulation of RNA splicing 3 0.6 8.94E-02 PQBP1, AFF2, MBNL3 
positive regulation of NF-kappaB transcription factor 
activity 6 1.2 8.95E-02 IRAK1, AR, CD40LG, IKBKG, EDA, MID2 
GABA-A receptor activity 3 0.6 9.03E-02 GABRE, GABRA3, GABRQ 
cell junction 7 1.4 9.58E-02 GABRE, PLXNA3, GABRA3, GLRA2, GRIA3, GLRA4, GABRQ 
Table 2. Enrichment analysis of gene ontology (GO) terms for X-linked genes 
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Figure 1 Boxplots of log2-transformed relative X chromosome expression (RXE) data in 
brain and major tissues. (A) RXE Boxplots of log2-transformed TPM values for major ovine 
tissues. (B) RXE Boxplots of log2-transformed TPM values for ovine brain tissues.  Red dots 
represent the mean X chromosome expression for all replicate libraries within a treatment group. 
Black dots represent the mean expression for each autosome. The red dotted line represents 
complete dosage compensation. Equal X expression with the autosomal chromosomes is indicated 
by an RXE value of 0, while halved X expression relative to the other chromosomes is indicated 
by an RXE value of -1. The autosomes with a mean expression that falls outside of the quartiles 
of the boxplot are numbered.  
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Figure 2 Boxplots of log2-transformed relative X chromosome expression (RXE) data in 
female and male specific tissues. RXE Boxplots of log2-transformed TPM values for ovine 
female specific and male specific tissues. Red dots represent the mean X chromosome expression 
for all replicate libraries within a treatment group. Black dots represent the mean expression for 
each autosome. The red dotted line represents complete dosage compensation. Equal X expression 
with the autosomal chromosomes is indicated by an RXE value of 0, while halved X expression 
relative to the other chromosomes is indicated by an RXE value of -1. The autosomes with a mean 
expression that falls outside of the quartiles of the boxplot are numbered. 
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Figure 3 Boxplots of log2-transformed relative X chromosome expression (RXE) data by 
nutritional treatment group. (A) Boxplots of log2-transformed TPM values displaying the mean 
X chromosome gene expression relative to the mean gene expression of all autosome for the 
Control treatment group. (B) RXE Boxplots for the Overfed treatment group. (C) RXE Boxplots 
for the Restricted treatment group. Red dots represent the mean X chromosome expression for all 
replicate libraries within a treatment group. Black dots represent the mean expression for each 
autosome. The red dotted line represents complete dosage compensation. Equal X expression with 
the autosomal chromosomes is indicated by an RXE value of 0, while halved X expression relative 
to the other chromosomes is indicated by an RXE value of -1. The autosomes with a mean 
expression that falls outside of the quartiles of the boxplot are numbered. 
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Figure 4. Top 10 X-linked genes expressed in control female and male fetal day 135 brain. 
(A) Top 10 X-linked genes expressed in control female brain. (B) Top 10 X-linked genes expressed 
in control male brain. Mean expression in TPM is plotted along with error bars for the standard 
error of the mean. The genes represented are PLP1 (Proteolipid Protein 1), TMSB4X (Thymosin 
Beta 4, X-Linked), RPL10 (Ribosomal Protein L10), GDI1 (GDP Dissociation Inhibitor 1), RPL39 
(Ribosomal Protein L39), TSPAN7 (Tetraspanin 7), GPM6B (Glycoprotein M6B), SYP 
(Synaptophysin), RPS4X (Ribosomal Protein S4, X-Linked), and NGFRAP1 (Nerve Growth 
Factor Receptor-Associated Protein 1) aka BEX3 (Brain Expressed X-Linked 3).  
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Figure 5. Top 10 X-linked genes expressed in control female and male fetal day 135 kidney. 
(A) Top 10 X-linked genes expressed in control female kidney. (B) Top 10 X-linked genes 
expressed in control male kidney. Mean expression in TPM is plotted along with error bars for the 
standard error of the mean. The genes represented are RPL10 (Ribosomal Protein L10), RPL39 
(Ribosomal Protein L39), TMSB4X (Thymosin Beta 4, X-Linked), RPS4X (Ribosomal Protein 
S4, X-Linked), RPL36A (Ribosomal Protein L36a), SAT1 (Spermidine/Spermine N1-
Acetyltransferase 1), GPC3 (Glypican 3), CAPN6 (Calpain 6), S100G (S100 Calcium Binding 
Protein G), SSR4 (Signal Sequence Receptor Subunit 4), PGRMC1 (Progesterone Receptor 
Membrane Component 1), BGN (Biglycan), and PGK1 (Phosphoglycerate Kinase 1).  
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Figure 6. Top 10 X-linked genes expressed in control female and male fetal day 135 lung. (A) 
Top 10 X-linked genes expressed in control female lung. (B) Top 10 X-linked genes expressed in 
control male lung. Mean expression in TPM is plotted along with error bars for the standard error 
of the mean. The genes represented are RPL10 (Ribosomal Protein L10), RPL39 (Ribosomal 
Protein L39), TMSB4X (Thymosin Beta 4, X-Linked), RPS4X (Ribosomal Protein S4, X-Linked), 
RPL36A (Ribosomal Protein L36a), PGRMC1 (Progesterone Receptor Membrane Component 1), 
SAT1 (Spermidine/Spermine N1-Acetyltransferase 1), MSN (Moesin), BGN (Biglycan), GPC3 
(Glypican 3), and FLNA (Filamin A).  
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Figure 7 Expressed X-linked genes in sheep day 135 brain, kidney, and lung in the ruminant 
pseudoautosomal region. The Human X chromosome (HSAX) shows the organization of the 
human pseudoautosomal regions (PAR1 and PAR2) and X-specific regions evolutionary strata 
(S1-S5). Pseudoautosomal boundaries are shown in pink text. Human PAR1 is 2.7 Mb starting at 
the gene PLCXD1 and ending at the gene XG and human PAR2 is 0.32 Mb. The ruminant PAR 
starts at the gene GTPB6P and ends at the gene GPR143. The ruminant PAR is 5-9 Mb. The gene 
PLCXD1 is X-specific in ruminants and is not located in the pseudoautosomal region. Its location 
is marked by the red line. The 14 expressed X-linked genes in this study that are in the ruminant 
PAR are enclosed in red boxes. The genes are P2RY8, DHRSX, ZBED1, CD99, XG, GYG2, 
ARSE, MXRA5, PRKX, NLGN4X, STS, PNPLA4, TBL1X, AND GPR143.  
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